HDAC Inhibitors
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 July 2011) | Viewed by 46175
Special Issue Editor
Interests: blood clotting; bleeding disorders; transfusion medics; myeloma therapy (clinical and pre-clinial)and biology; cutaneous T cell lymphoma (clinical); immunotherapy; epigenetics
Special Issue Information
Dear Colleagues,
Histone deacetylase inhibitors are clearly effective therapeutic tools in the treatment of cancers, particularly haematological malignancies. The purpose of this special issue is to provide the reader with a focused review of on the current place of HDACi as a therapy, particularly in blood cancers. We hope to provide a broad overview of the rationale behind their use, with specific papers focusing on diseases where they clearly have biological effects - NHL, Hodgkin disease, myeloid malignancies. Finally we hope to have two seperate papers examining mechanisms of resistance and common toxicities.
I hope you will be able to contribute to what I see will be a valuable compendium of insightful reviews in this very topical subject.
Prof. Dr. H. Miles Prince
Guest Editors
Keywords
- histone deacetylase
- epigenetics
- demethylation
- novel therapies
- transcription factors